US20080102095A1 - Acidic processes to prepare antimicrobial contact lenses - Google Patents

Acidic processes to prepare antimicrobial contact lenses Download PDF

Info

Publication number
US20080102095A1
US20080102095A1 US11/923,685 US92368507A US2008102095A1 US 20080102095 A1 US20080102095 A1 US 20080102095A1 US 92368507 A US92368507 A US 92368507A US 2008102095 A1 US2008102095 A1 US 2008102095A1
Authority
US
United States
Prior art keywords
solution
lens
acidic substance
silver
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/923,685
Inventor
Kent Young
Osman Rathore
Nayiby Alvarez-Carrigan
David Turner
Frank Neely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Vision Care Inc
Original Assignee
Johnson and Johnson Vision Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Vision Care Inc filed Critical Johnson and Johnson Vision Care Inc
Priority to US11/923,685 priority Critical patent/US20080102095A1/en
Assigned to JOHNSON & JOHNSON VISION CARE, INC. reassignment JOHNSON & JOHNSON VISION CARE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEELY, FRANK, YOUNG, KENT, RATHORE, OSMAN, ALVAREZ-CARRIGAN, NAYIBY, TURNER, DAVID
Publication of US20080102095A1 publication Critical patent/US20080102095A1/en
Priority to US13/007,776 priority patent/US9358317B2/en
Priority to US15/146,426 priority patent/US20160242421A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/088Heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041Lenses
    • G02B1/043Contact lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/106Halogens or compounds thereof, e.g. iodine, chlorite

Definitions

  • This invention relates to methods of preparing antimicrobial lenses
  • the first contact lenses were made of hard materials. They were used by a patient during waking hours and removed for cleaning. Current developments in the field gave rise to soft contact lenses, which may be worn continuously, for several days or more without removal for cleaning. Although many patients favor these lenses due to their increased comfort, these lenses can cause some adverse reactions to the user.
  • the extended use of the lenses can encourage the buildup of bacteria or other microbes, particularly, Pseudomonas aeruginosa , on the surfaces of soft contact lenses. The build-up of bacteria and other microbes can cause adverse side effects such as contact lens acute red eye and the like. Although the problem of bacteria and other microbes is most often associated with the extended use of soft contact lenses, the build-up of bacteria and other microbes occurs for users of hard contact lens wearers as well.
  • FIG. 1 Silver content vs Sodium Iodide concentration in a neutral process.
  • FIG. 2 Silver content vs Sodium Iodide in an acidified process.
  • This invention includes a method of preparing an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, wherein said method comprising the steps of
  • the term “acidic substance” refers to a composition may be added to a solution to reduce the pH of said solution to a pH of less than 7.
  • acidic substances include but are not limited to acetic acid, sulfuric acid, and hydrochloric acid.
  • the preferred acidic substance is acetic acid.
  • effective amount refers to the concentration of the acidic substance required to reduce the pH of the solution to less than 7. It is preferable that the effective amount reduce the pH of the solution to less, than about 5, more preferably to less than about 4, most preferably less than about 3.6.
  • the preferred acidic substance, acetic acid is present in a concentration of about 0.01% to about 10% (weight percent, based on the total weight of the solution), more preferably about 0.5%, most preferably about 0.05%.
  • the acidic substance in step (a) and step (b) may be the same or different. It is preferred that the acidic substance of steps (a) and (b) are the same.
  • metal salt means any molecule having the general formula [M] a [X] b wherein X contains any negatively charged ion, a is >1, b is >1 and M is any positively charged metal selected from, but not limited to, the following Al +3 , Co +2 , Co +3 , Ca +2 , Mg +2 , Ni +2 , Ti +2 , Ti +3 , Ti +4 , V +2 , V +3 , V +5 , Sr +2 , Fe +2 , Fe +3 , Ag +1 , Ag +2 , Au +2 , Au +3 , Au +1 , Pd +2 , Pd +4 , Pt +2 , Pt +4 Cu +1 Cu +2 , Mn +2 , Mn +3 , Mn +4 , Zn +2 , and the like.
  • Examples of X include but are not limited to CO 3 ⁇ 2 , NO 3 ⁇ 1 , PO 4 ⁇ 3 , Cl ⁇ 1 , I ⁇ 1 , Br ⁇ 1 , S ⁇ 2 , O ⁇ 2 and the like. Further X includes negatively charged ions containing CO 3 ⁇ 2 NO 3 ⁇ 1 , PO 4 ⁇ 3 , Cl ⁇ 1 , I ⁇ 1 , Br ⁇ 1 , S ⁇ 2 , O ⁇ 2 , and the like, such as C 1-5 alkylCO 2 ⁇ 1 .
  • the term metal salts does not include zeolites, disclosed in WO03/011351. This patent application is hereby incorporated by reference in its entirety. The preferred a is 1, 2, or 3.
  • the preferred b is 1, 2, or 3.
  • the preferred metals ions are Mg +2 , Zn +2 , Cu +1 , Cu +2 , Au +2 , Au +3 , Au +1 , Pd +2 , Pd +4 , Pt +2 , Pt +4 , Ag +2 , and Ag +1 .
  • the particularly preferred metal ion is Ag +1 .
  • suitable metal salts include but are not limited to manganese sulfide, zinc oxide, zinc sulfide, copper sulfide, and copper phosphate.
  • silver salts include but are not limited to silver nitrate, silver sulfate, silver iodate, silver carbonate, silver phosphate, silver sulfide, silver chloride, silver bromide, silver iodide, and silver oxide.
  • the preferred silver salts are silver iodide, silver chloride, and silver bromide.
  • the amount of metal in the lenses is measured based upon the total weight of the lenses.
  • the metal is silver
  • the preferred amount of silver is about 0.00001 weight percent (0.1 ppm) to about 10.0 weight percent, preferably about 0.0001 weight percent (1 ppm) to about 1.0 weight percent, most preferably about 0.001 weight percent (10 ppm) to about 0.1 weight percent, based on the dry weight of the lens.
  • the molecular weight of the metal salts determines the conversion of weight percent of metal ion to metal salt.
  • the preferred amount of silver salt is about 0.00003 weight percent (0.3 ppm) to about 30.0 weight percent, preferably about 0.0003 weight percent (3 ppm) to about 3.0 weight percent, most preferably about 0.003 weight percent (30 ppm) to about 0.3 weight percent, based on the dry weight of the lens.
  • salt precursor refers to any compound or composition (including aqueous solutions) that contains a cation that may be substituted with metal ions.
  • concentration of salt precursor in its solution is between about 0.00001 to about 10.0 weight percent, (0.1-100,000 ppm) more preferably about 0.0001 to about 1.0 weight percent, (1-10,000 ppm) most preferably about 0.001 to about 0.1 weight percent (10-1000 ppm) based upon the total weight of the solution.
  • salt precursors include but are not limited to inorganic molecules such as sodium chloride, sodium iodide, sodium bromide, sodium sulfide, lithium chloride, lithium iodide, lithium bromide, lithium sulfide, potassium bromide, potassium chloride, potassium sulfide, potassium iodide, rubidium iodide, rubidium bromide, rubidium chloride, rubidium sulfide, caesium iodide, caesium bromide, caesium chloride, caesium sulfide, francium iodide, francium bromide, francium chloride, francium sulfide, sodium tetrachloro argentite, and the like.
  • inorganic molecules such as sodium chloride, sodium iodide, sodium bromide, sodium sulfide, lithium chloride, lithium iodide, lithium bromide, lithium sulf
  • organic molecules include but are not limited to tetra-alkyl ammonium lactate, tetra-alkyl ammonium sulfate, quaternary ammonium halides, such as tetra-alkyl ammonium chloride, bromide or iodide.
  • the preferred salt precursor is selected from the group consisting of sodium chloride, sodium iodide, sodium bromide, lithium chloride, lithium sulfide, sodium sulfide, potassium sulfide, potassium iodide, and sodium tetrachloro argentite and the particularly preferred salt precursor is sodium iodide.
  • metal agent refers to any composition (including aqueous solutions) containing metal ions.
  • compositions include but are not limited to aqueous or organic solutions of silver nitrate, silver triflate, or silver acetate, silver tetrafluoroborate, silver sulfate, zinc acetate, zinc sulfate, copper acetate, and copper sulfate, where the concentration of metal agent in solution is about 1 ⁇ g/mL or greater.
  • the preferred metal agent is aqueous silver nitrate, where the concentration of silver nitrate is the solution is about greater than or equal to 0.0001 to about 2 weight percent, more preferably about greater than 0.001 to about 0.01 weight percent based on the total weight of the solution.
  • solution refers to an aqueous substance such as deionized water, saline solutions, borate or buffered saline solution, or organic substance such as C1-C24 alcohols, cyclic amides, acyclic amides, ethers and acids.
  • treating refers to any method of contacting solutions of the metal agent and the acidic substance or, the salt precursor and the acidic substance, with the lens, where the preferred method is immersing the lens in a solution of containing either the metal agent and the acidic substance or the salt precursor and the acidic substance. Treating can include heating the lens in these solutions, but it preferred that treating is carried out at ambient temperatures.
  • the time of treating is preferably about 1 minute to 24 hours, most preferably about 3 minute to about 30 minutes
  • lens refers to an ophthalmic device that resides in or on the eye. These devices can provide optical correction, wound care, drug delivery, diagnostic functionality, cosmetic enhancement or effect or a combination of these properties.
  • the term lens includes but is not limited to soft contact lenses, hard contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts.
  • Soft contact lenses are made from silicone elastomers or hydrogels, which include but are not limited to silicone hydrogels, and fluorohydrogels.
  • lens includes but is not limited to those made from the soft contact lens formulations described in U.S. Pat. No. 5,710,302, WO 9421698, EP 406161, JP 2000016905, U.S. Pat. No. 5,998,498, U.S. patent application Ser. No. 09/532,943, U.S. Pat. No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776,999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No. 5,965,631.
  • soft contact lenses formulations include but are not limited to the formulations of etafilcon A, balafilcon A, bufilcon A, deltafilcon A, droxifilcon A, phemfilcon A, ocufilicon A, perfilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, metafilcon A, B, vifilcon A focofilcon A, tetrafilcon B, and silicone hydrogels, as prepared in U.S. Pat. No. 5,998,498, U.S. Ser. No. 09/532,943, a continuation-in-part of U.S. patent application Ser. No. 09/532,943, filed on Aug.
  • Lenses of the invention may be made from silicone hydrogel components.
  • a silicone-containing component is one that contains at least one [—Si—O—Si] group, in a monomer, macromer or prepolymer.
  • the Si and attached O are present in the silicone-containing component in an amount greater than 20 weight percent, and more preferably greater than 30 weight percent of the total molecular weight of the silicone-containing component.
  • Useful silicone-containing components preferably comprise polymerizable functional groups such as acrylate, methacrylate, acrylamide, methacrylamide, N-vinyl lactam, N-vinylamide, and styryl functional groups.
  • silicone components which may be included in the silicone hydrogel formulations include, but are not limited to silicone macromers, prepolymers and monomers.
  • silicone macromers include, without limitation, polydimethylsiloxane methacrylated with pendant hydrophilic groups as described in U.S. Pat. Nos. 4,259,467; 4,260,725 and 4,261,875; polydimethylsiloxane macromers with polymerizable functional group(s) described in U.S. Pat. Nos.
  • Suitable silicone monomers include tris(trimethylsiloxy)silylpropyl methacrylate, hydroxyl functional silicone containing monomers, such as 3-methacryloxy-2-hydroxypropyloxy)propylbis(trimethylsiloxy)methylsilane and those disclosed in WO03/22321, and mPDMS containing or the siloxane monomers described in U.S. Pat. Nos.
  • siloxane containing monomers include, amide analogs of TRIS described in U.S. Pat. No. 4,711,943, vinylcarbamate or carbonate analogs described in U.S. Pat. No. 5,070,215, and monomers contained in U.S. Pat. No. 6,020,445, monomethacryloxypropyl terminated polydimethylsiloxanes, polydimethylsiloxanes, 3-methacryloxypropylbis(trimethylsiloxy)methylsilane, methacryloxypropylpentamethyl disiloxane and combinations thereof.
  • hard contact lenses may be used.
  • hard contact lens formulations are made from polymers that include but are not limited to polymers of poly(methyl)methacrylate, silicon acrylates, silicone acrylates, fluoroacrylates, fluoroethers, polyacetylenes, and polyimides, where the preparation of representative examples may be found in JP 200010055, JP 6123860 and U.S. Pat. No. 4,330,383.
  • Intraocular lenses of the invention can be formed using known materials.
  • the lenses may be made from a rigid material including, without limitation, polymethyl methacrylate, polystyrene, polycarbonate, or the like, and combinations thereof.
  • flexible materials may be used including, without limitation, hydrogels, silicone materials, acrylic materials, fluorocarbon materials and the like, or combinations thereof.
  • Typical intraocular lenses are described in WO 0026698, WO 0022460, WO 9929750, WO 9927978, WO 0022459, and JP 2000107277.
  • the lenses of the invention are optically clear, with optical clarity comparable to lenses such as lenses made from etafilcon A, genfilcon A, galyfilcon A, lenefilcon A, polymacon, acquafilcon A, balafilcon A, and lotrafilcon A.
  • the most preferred lens formulations are those used to prepare ionic lenses. Monomers that are useful in the preparation of such lenses include methacrylic acid and the like.
  • lens formulations examples include those used to prepare etafilcon A, balafilcon A, bufilcon A, deltafilcon A, droxifilcon A, phemfilcon A, ocufilicon A, perfilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, metafilcon A, B, vifilcon A focofilcon A, and tetrafilcon B
  • lens formulations cited above may allow a user to insert the lenses for a continuous period of time ranging from one day to thirty days. It is known that the longer a lens is on the eye, the greater the chance that bacteria and other microbes will build up on the surface of those lenses. Therefore there is a need to develop lenses that release antimicrobial agents such as silver, over an extended period of time.
  • cured refers to any of a number of methods used to react a mixture of lens components (ie, momoner, prepolymers, macromers and the like) to form lenses.
  • Lenses can be cured by light or heat.
  • the preferred method of curing is with radiation, preferably UV or visible light, and most preferably with visible light.
  • the lens formulations of the present invention can be formed by any of the methods know to those skilled in the art, such as shaking or stirring, and used to form polymeric articles or devices by known methods.
  • the antimicrobial lenses of the invention may be prepared by mixing reactive components and any diluent(s) with a polymerization initiator and curing by appropriate conditions to form a product that can be subsequently formed into the appropriate shape by lathing, cutting and the like.
  • the reaction mixture may be placed in a mold and subsequently cured into the appropriate article.
  • the lens formulation is placed in a mold having the approximate shape of the final desired lens, and the lens formulation is subjected to conditions whereby the components polymerize, to produce a hardened disc that is subjected to a number of different processing steps including treating the polymerized lens with liquids (such as water, inorganic salts, or organic solutions) to swell, or otherwise equilibrate this lens prior to enclosing the lens in its final packaging.
  • liquids such as water, inorganic salts, or organic solutions
  • the invention includes a method of preparing an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, wherein the method comprises, consists essentially of, or consists of the steps of
  • an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, prepared by a method comprising the steps of
  • the invention includes an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, prepared by a method comprising the steps of
  • Blue HEMA the reaction product of reactive blue number 4 and HEMA, as described in Example 4 or U.S. Pat. No. 5,944,853
  • CGI 819 bis(2,4,6-trimethylbenzoyl)phenylphosphineoxide
  • HEMA hydroxyethyl methacrylate
  • MAA methacrylic acid
  • mPDMS mono-methacryloxypropyl terminated polydimethylsiloxane (MW 800-1000)
  • acPDMS bis-3-acryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane
  • ppm parts per million micrograms of sample per gram of dry lens
  • PVP polyvinylpyrrolidinone (360,000 or 2,500)
  • SSPS Sodium Sulfate Packing Solution
  • a hydrogel blend was made from the following monomer mix (all amounts were calculated as weight percent: 30.00% SIMM 2, 28.0% mPDMS, 5.0% acPDMS, 19.0% DMA, 7.15% HEMA, 1.60% MM, 7.00% PVP 360,000, 2.0% Norbloc, 1.0% CGI 819 and 0.02% Blue HEMA, 60 weight percent of the preceding component mixture was further diluted with diluent, 40 weight percent of 72.5:27.5 TAA: PVP 2,500, to form the final monomer mix.
  • the blend placed in a two part contact lens mold and was cured using the following sequential conditions a) room temperature for 30 seconds using a visible light that emits 1 mW/sq cm, b)75° C. 120 seconds, c) 75° C. 120 seconds 1.8 mW/sq/cm, and d) 75° C. 240 seconds 6.0 mW/sq cm.
  • the cured lenses are removed from the molds and hydrated with Di.
  • Cured and hydrated lenses of Type A are placed in a jar with sodium iodide solution in deionized water (500-700 ppm), containing 50 ppm of methylcellulose ( ⁇ 3 mL solution per lens,) and rolled on a jar roller overnight.
  • the lenses were transferred from the jar to a blister pack where the excess sodium iodide solution was removed.
  • the silver nitrate solution was removed, and the lenses were placed in a jar containing deionized water and rolled on a jar roller for approximately thirty minutes.
  • the deionized water was replaced with borate buffered sodium sulfate solution containing 50 ppm methylcellulose water (SSPS), and allowed to roll on the jar roller for an additional 30 minutes. The solution was then replaced with fresh SSPS.
  • the lenses were then transferred to new blisters and dosed with 950 ⁇ L of SSPS.
  • the blisters were sealed and autoclaved at 125° C. for 18 minutes and analyzed for silver content using the method described below.
  • the results are presented in FIG. 1 . This data shows that increasing the concentration of sodium iodide, unexpectedly reduces the amount of silver iodide deposited into the lens.
  • INAA Instrumental Neutron Activation Analysis
  • Example 2 The procedure of Example 1 was repeated with one exception, 0.05% weight percent of Acetic Acid in deionized water was added to the sodium iodide solution and the silver nitrate solution. The lenses were analyzed for silver content and the data is presented in FIG. 2 . This data shows that the acidified process gives the expected increase in the amount of silver iodide deposited in the lens as the amount of sodium nitrate is increased.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Eyeglasses (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Surface Treatment Of Glass (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to antimicrobial lenses containing metals and methods for their production.

Description

    RELATED APPLICATION
  • This application is a non-provisional filing of a provisional application, U.S. Ser. No. 60/863,583, filed on Oct. 31, 2006.
  • FIELD OF THE INVENTION
  • This invention relates to methods of preparing antimicrobial lenses
  • BACKGROUND OF THE INVENTION
  • Contact lenses have been used commercially to improve vision since the 1950s. The first contact lenses were made of hard materials. They were used by a patient during waking hours and removed for cleaning. Current developments in the field gave rise to soft contact lenses, which may be worn continuously, for several days or more without removal for cleaning. Although many patients favor these lenses due to their increased comfort, these lenses can cause some adverse reactions to the user. The extended use of the lenses can encourage the buildup of bacteria or other microbes, particularly, Pseudomonas aeruginosa, on the surfaces of soft contact lenses. The build-up of bacteria and other microbes can cause adverse side effects such as contact lens acute red eye and the like. Although the problem of bacteria and other microbes is most often associated with the extended use of soft contact lenses, the build-up of bacteria and other microbes occurs for users of hard contact lens wearers as well.
  • Others have taught that the addition of antibacterial agents such as metal salts to contact lenses can inhibit the growth of bacteria or other microbes. See, US 2004/0150788, which is hereby incorporated by reference in its entirety. In order produce manufacturing quantities of contact lenses containing antibacterial agents, processes to prepare these lenses must give consistent results. When some of the processes disclosed in US 2004-0150788 are used with different contact lens formulations, the contact lenses that are produced have variable amounts of antibacterial agents contained therein. Since the amount of antibacterial agent in every lens must be consistent from lot to lot, it is desirable to find process to prepare contact lenses containing antibacterial agents that produce a consistent product. This need is met by the following invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 Silver content vs Sodium Iodide concentration in a neutral process.
  • FIG. 2. Silver content vs Sodium Iodide in an acidified process.
  • DETAILED DESCRIPTION OF THE INVENTION
  • This invention includes a method of preparing an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, wherein said method comprising the steps of
      • (a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
      • (b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
        As used herein, the term, “antimicrobial lens” means a lens that exhibits one or more of the following properties, the inhibition of the adhesion of bacteria or other microbes to the lenses, the inhibition of the growth of bacteria or other microbes on lenses, and the killing of bacteria or other microbes on the surface of lenses or in an area surrounding the lenses. For purposes of this invention, adhesion of bacteria or other microbes to lenses, the growth of bacteria or other microbes on lenses and the presence of bacteria or other microbes on the surface of lenses are collectively referred to as “microbial colonization.” Preferably, the lenses of the invention exhibit a reduction of viable bacteria or other microbe of at least about 0.25 log, more preferably at least about 0.5 log, most preferably at least about 1.0 log L>90% inhibition). Such bacteria or other microbes include but are not limited to those organisms found in the eye, particularly Pseudomonas aeruginosa, Acanthamoeba species, Staphylococcus. aureus, Escherichia. coli, Staphylococcus epidermidis, and Serratia marcesens.
  • As used herein, the term “acidic substance” refers to a composition may be added to a solution to reduce the pH of said solution to a pH of less than 7. Examples of acidic substances include but are not limited to acetic acid, sulfuric acid, and hydrochloric acid. The preferred acidic substance is acetic acid. The term “effective amount” refers to the concentration of the acidic substance required to reduce the pH of the solution to less than 7. It is preferable that the effective amount reduce the pH of the solution to less, than about 5, more preferably to less than about 4, most preferably less than about 3.6. The preferred acidic substance, acetic acid, is present in a concentration of about 0.01% to about 10% (weight percent, based on the total weight of the solution), more preferably about 0.5%, most preferably about 0.05%. The acidic substance in step (a) and step (b) may be the same or different. It is preferred that the acidic substance of steps (a) and (b) are the same.
  • As use herein, the term “metal salt” means any molecule having the general formula [M]a [X]b wherein X contains any negatively charged ion, a is >1, b is >1 and M is any positively charged metal selected from, but not limited to, the following Al+3, Co+2, Co+3, Ca+2, Mg+2, Ni+2, Ti+2, Ti+3, Ti+4, V+2, V+3, V+5, Sr+2, Fe+2, Fe+3, Ag+1, Ag+2, Au+2, Au+3, Au+1, Pd+2, Pd+4, Pt+2, Pt+4 Cu+1 Cu+2, Mn+2, Mn+3, Mn+4, Zn+2, and the like. Examples of X include but are not limited to CO3 −2, NO3 −1, PO4 −3, Cl−1, I−1, Br−1, S−2, O−2 and the like. Further X includes negatively charged ions containing CO3 −2 NO3 −1, PO4 −3, Cl−1, I−1, Br−1, S−2, O−2, and the like, such as C1-5alkylCO2 −1. As used herein the term metal salts does not include zeolites, disclosed in WO03/011351. This patent application is hereby incorporated by reference in its entirety. The preferred a is 1, 2, or 3. The preferred b is 1, 2, or 3. The preferred metals ions are Mg+2, Zn+2, Cu+1, Cu+2, Au+2, Au+3, Au+1, Pd+2, Pd+4, Pt+2, Pt+4, Ag+2, and Ag+1. The particularly preferred metal ion is Ag+1. Examples of suitable metal salts include but are not limited to manganese sulfide, zinc oxide, zinc sulfide, copper sulfide, and copper phosphate. Examples of silver salts include but are not limited to silver nitrate, silver sulfate, silver iodate, silver carbonate, silver phosphate, silver sulfide, silver chloride, silver bromide, silver iodide, and silver oxide. The preferred silver salts are silver iodide, silver chloride, and silver bromide.
  • The amount of metal in the lenses is measured based upon the total weight of the lenses. When the metal is silver, the preferred amount of silver is about 0.00001 weight percent (0.1 ppm) to about 10.0 weight percent, preferably about 0.0001 weight percent (1 ppm) to about 1.0 weight percent, most preferably about 0.001 weight percent (10 ppm) to about 0.1 weight percent, based on the dry weight of the lens. With respect to adding metal salts, the molecular weight of the metal salts determines the conversion of weight percent of metal ion to metal salt. The preferred amount of silver salt is about 0.00003 weight percent (0.3 ppm) to about 30.0 weight percent, preferably about 0.0003 weight percent (3 ppm) to about 3.0 weight percent, most preferably about 0.003 weight percent (30 ppm) to about 0.3 weight percent, based on the dry weight of the lens.
  • The term “salt precursor” refers to any compound or composition (including aqueous solutions) that contains a cation that may be substituted with metal ions. The concentration of salt precursor in its solution is between about 0.00001 to about 10.0 weight percent, (0.1-100,000 ppm) more preferably about 0.0001 to about 1.0 weight percent, (1-10,000 ppm) most preferably about 0.001 to about 0.1 weight percent (10-1000 ppm) based upon the total weight of the solution. Examples of salt precursors include but are not limited to inorganic molecules such as sodium chloride, sodium iodide, sodium bromide, sodium sulfide, lithium chloride, lithium iodide, lithium bromide, lithium sulfide, potassium bromide, potassium chloride, potassium sulfide, potassium iodide, rubidium iodide, rubidium bromide, rubidium chloride, rubidium sulfide, caesium iodide, caesium bromide, caesium chloride, caesium sulfide, francium iodide, francium bromide, francium chloride, francium sulfide, sodium tetrachloro argentite, and the like. Examples of organic molecules include but are not limited to tetra-alkyl ammonium lactate, tetra-alkyl ammonium sulfate, quaternary ammonium halides, such as tetra-alkyl ammonium chloride, bromide or iodide. The preferred salt precursor is selected from the group consisting of sodium chloride, sodium iodide, sodium bromide, lithium chloride, lithium sulfide, sodium sulfide, potassium sulfide, potassium iodide, and sodium tetrachloro argentite and the particularly preferred salt precursor is sodium iodide.
  • The term “metal agent” refers to any composition (including aqueous solutions) containing metal ions. Examples of such compositions include but are not limited to aqueous or organic solutions of silver nitrate, silver triflate, or silver acetate, silver tetrafluoroborate, silver sulfate, zinc acetate, zinc sulfate, copper acetate, and copper sulfate, where the concentration of metal agent in solution is about 1 μg/mL or greater. The preferred metal agent is aqueous silver nitrate, where the concentration of silver nitrate is the solution is about greater than or equal to 0.0001 to about 2 weight percent, more preferably about greater than 0.001 to about 0.01 weight percent based on the total weight of the solution.
  • The term “solution” refers to an aqueous substance such as deionized water, saline solutions, borate or buffered saline solution, or organic substance such as C1-C24 alcohols, cyclic amides, acyclic amides, ethers and acids.
  • The term “treating” refers to any method of contacting solutions of the metal agent and the acidic substance or, the salt precursor and the acidic substance, with the lens, where the preferred method is immersing the lens in a solution of containing either the metal agent and the acidic substance or the salt precursor and the acidic substance. Treating can include heating the lens in these solutions, but it preferred that treating is carried out at ambient temperatures. The time of treating is preferably about 1 minute to 24 hours, most preferably about 3 minute to about 30 minutes
  • As used herein, the term “lens” refers to an ophthalmic device that resides in or on the eye. These devices can provide optical correction, wound care, drug delivery, diagnostic functionality, cosmetic enhancement or effect or a combination of these properties. The term lens includes but is not limited to soft contact lenses, hard contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts. Soft contact lenses are made from silicone elastomers or hydrogels, which include but are not limited to silicone hydrogels, and fluorohydrogels.
  • For example the term lens includes but is not limited to those made from the soft contact lens formulations described in U.S. Pat. No. 5,710,302, WO 9421698, EP 406161, JP 2000016905, U.S. Pat. No. 5,998,498, U.S. patent application Ser. No. 09/532,943, U.S. Pat. No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776,999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No. 5,965,631. Examples of soft contact lenses formulations include but are not limited to the formulations of etafilcon A, balafilcon A, bufilcon A, deltafilcon A, droxifilcon A, phemfilcon A, ocufilicon A, perfilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, metafilcon A, B, vifilcon A focofilcon A, tetrafilcon B, and silicone hydrogels, as prepared in U.S. Pat. No. 5,998,498, U.S. Ser. No. 09/532,943, a continuation-in-part of U.S. patent application Ser. No. 09/532,943, filed on Aug. 30, 2000, WO03/22321, U.S. Pat. No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776,999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No. 5,965,631. These patents as well as all other patent disclosed in this paragraph are hereby incorporated by reference in their entirety.
  • Lenses of the invention may be made from silicone hydrogel components. A silicone-containing component is one that contains at least one [—Si—O—Si] group, in a monomer, macromer or prepolymer. Preferably, the Si and attached O are present in the silicone-containing component in an amount greater than 20 weight percent, and more preferably greater than 30 weight percent of the total molecular weight of the silicone-containing component. Useful silicone-containing components preferably comprise polymerizable functional groups such as acrylate, methacrylate, acrylamide, methacrylamide, N-vinyl lactam, N-vinylamide, and styryl functional groups. Examples of silicone components which may be included in the silicone hydrogel formulations include, but are not limited to silicone macromers, prepolymers and monomers. Examples of silicone macromers include, without limitation, polydimethylsiloxane methacrylated with pendant hydrophilic groups as described in U.S. Pat. Nos. 4,259,467; 4,260,725 and 4,261,875; polydimethylsiloxane macromers with polymerizable functional group(s) described in U.S. Pat. Nos. 4,136,250; 4,153,641; 4,189,546; 4,182,822; 4,343,927; 4,254,248; 4,355,147; 4,276,402; 4,327,203; 4,341,889; 4,486,577; 4,605,712; 4,543,398; 4,661,575; 4,703,097; 4,837,289; 4,954,586; 4,954,587; 5,346,946; 5,358,995; 5,387,632; 5,451,617; 5,486,579; 5,962,548; 5,981,615; 5,981,675; and 6,039,913; polysiloxane macromers incorporating hydrophilic monomers such as those described in U.S. Pat. Nos. 5,010,141; 5,057,578; 5,314,960; 5,371,147 and 5,336,797; macromers comprising polydimethylsiloxane blocks and polyether blocks such as those described in U.S. Pat. Nos. 4,871,785 and 5,034,461, combinations thereof and the like. All of the patents cited herein are hereby incorporated in their entireties by reference.
  • The silicone and/or fluorine containing macromers described in U.S. Pat. Nos. 5,760,100; 5,776,999; 5,789,461; 5,807,944; 5,965,631 and 5,958,440 may also be used. Suitable silicone monomers include tris(trimethylsiloxy)silylpropyl methacrylate, hydroxyl functional silicone containing monomers, such as 3-methacryloxy-2-hydroxypropyloxy)propylbis(trimethylsiloxy)methylsilane and those disclosed in WO03/22321, and mPDMS containing or the siloxane monomers described in U.S. Pat. Nos. 4,120,570, 4,139,692, 4,463,149, 4,450,264, 4,525,563; 5,998,498; 3,808,178; 4,139,513; 5,070,215; 5,710,302; 5,714,557 and 5,908,906.
  • Additional suitable siloxane containing monomers include, amide analogs of TRIS described in U.S. Pat. No. 4,711,943, vinylcarbamate or carbonate analogs described in U.S. Pat. No. 5,070,215, and monomers contained in U.S. Pat. No. 6,020,445, monomethacryloxypropyl terminated polydimethylsiloxanes, polydimethylsiloxanes, 3-methacryloxypropylbis(trimethylsiloxy)methylsilane, methacryloxypropylpentamethyl disiloxane and combinations thereof.
  • In addition to soft contact lens formulations, hard contact lenses may be used. Examples of hard contact lens formulations are made from polymers that include but are not limited to polymers of poly(methyl)methacrylate, silicon acrylates, silicone acrylates, fluoroacrylates, fluoroethers, polyacetylenes, and polyimides, where the preparation of representative examples may be found in JP 200010055, JP 6123860 and U.S. Pat. No. 4,330,383. Intraocular lenses of the invention can be formed using known materials. For example, the lenses may be made from a rigid material including, without limitation, polymethyl methacrylate, polystyrene, polycarbonate, or the like, and combinations thereof. Additionally, flexible materials may be used including, without limitation, hydrogels, silicone materials, acrylic materials, fluorocarbon materials and the like, or combinations thereof. Typical intraocular lenses are described in WO 0026698, WO 0022460, WO 9929750, WO 9927978, WO 0022459, and JP 2000107277. U.S. Pat. Nos. 4,301,012; 4,872,876; 4,863,464; 4,725,277; 4,731,079. All of the references mentioned in this application are hereby incorporated by reference in their entirety.
  • Preferably, the lenses of the invention are optically clear, with optical clarity comparable to lenses such as lenses made from etafilcon A, genfilcon A, galyfilcon A, lenefilcon A, polymacon, acquafilcon A, balafilcon A, and lotrafilcon A. The most preferred lens formulations are those used to prepare ionic lenses. Monomers that are useful in the preparation of such lenses include methacrylic acid and the like. Examples of the most preferred lens formulations include those used to prepare etafilcon A, balafilcon A, bufilcon A, deltafilcon A, droxifilcon A, phemfilcon A, ocufilicon A, perfilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, metafilcon A, B, vifilcon A focofilcon A, and tetrafilcon B
  • Many of the lens formulations cited above may allow a user to insert the lenses for a continuous period of time ranging from one day to thirty days. It is known that the longer a lens is on the eye, the greater the chance that bacteria and other microbes will build up on the surface of those lenses. Therefore there is a need to develop lenses that release antimicrobial agents such as silver, over an extended period of time.
  • The term “cured” refers to any of a number of methods used to react a mixture of lens components (ie, momoner, prepolymers, macromers and the like) to form lenses. Lenses can be cured by light or heat. The preferred method of curing is with radiation, preferably UV or visible light, and most preferably with visible light. The lens formulations of the present invention can be formed by any of the methods know to those skilled in the art, such as shaking or stirring, and used to form polymeric articles or devices by known methods.
  • For example, the antimicrobial lenses of the invention may be prepared by mixing reactive components and any diluent(s) with a polymerization initiator and curing by appropriate conditions to form a product that can be subsequently formed into the appropriate shape by lathing, cutting and the like. Alternatively, the reaction mixture may be placed in a mold and subsequently cured into the appropriate article.
  • Various processes are known for processing the lens formulation in the production of contact lenses, including spincasting and static casting. Spincasting methods are disclosed in U.S. Pat. Nos. 3,408,429 and 3,660,545, and static casting methods are disclosed in U.S. Pat. Nos. 4,113,224 and 4,197,266. The preferred method for producing antimicrobial lenses of this invention is by molding. In the case of hydrogel lenses, for this method, the lens formulation is placed in a mold having the approximate shape of the final desired lens, and the lens formulation is subjected to conditions whereby the components polymerize, to produce a hardened disc that is subjected to a number of different processing steps including treating the polymerized lens with liquids (such as water, inorganic salts, or organic solutions) to swell, or otherwise equilibrate this lens prior to enclosing the lens in its final packaging. This method is further described in U.S. Pat. Nos. 4,495,313; 4,680,336; 4,889,664; and 5,039,459, incorporated herein by reference. Polymerized lenses that have not been swelled or otherwise equilibrated are considered cured lenses for purposes of this invention.
  • Further, the invention includes a method of preparing an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, wherein the method comprises, consists essentially of, or consists of the steps of
      • (a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
      • (b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
        The terms antimicrobial lens, metal salt, salt precursor, metal agent, effective amount and treating all have their aforementioned meanings and preferred ranges.
  • Still further the invention includes an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, prepared by a method comprising the steps of
      • (a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
      • (b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
        The terms antimicrobial lens, metal salt, salt precursor, metal agent, effective amount and treating all have their aforementioned meanings and preferred ranges.
  • Yet still further, the invention includes an antimicrobial lens comprising, consisting essentially of, or consisting of a metal salt, prepared by a method comprising the steps of
      • (a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
      • (b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
        The terms antimicrobial lens, metal salt, salt precursor, metal agent, effective amount and treating all have their aforementioned meanings and preferred ranges.
  • In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in contact lenses as well as other specialties may find other methods of practicing the invention. However, those methods are deemed to be within the scope of this invention.
  • EXAMPLES
  • The following abbreviations were used in the examples
  • Blue HEMA=the reaction product of reactive blue number 4 and HEMA, as described in Example 4 or U.S. Pat. No. 5,944,853
  • CGI 819=bis(2,4,6-trimethylbenzoyl)phenylphosphineoxide
  • DI water=deionized water
  • DMA=N,N-dimethylacrylamide
  • HEMA=hydroxyethyl methacrylate
  • MAA=methacrylic acid;
  • mPDMS=mono-methacryloxypropyl terminated polydimethylsiloxane (MW 800-1000)
  • acPDMS=bis-3-acryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane
  • Norbloc=2-(2′-hydroxy-5-methacrylyloxyethylphenyl)-2H-benzotriazole
  • ppm=parts per million micrograms of sample per gram of dry lens
  • PVP=polyvinylpyrrolidinone (360,000 or 2,500)
  • Simma 2=3-methacryloxy-2-hydroxypropyloxy)propylbis (trimethylsiloxy)methylsilane
  • TAA=t-amyl alcohol
  • Sodium Sulfate Packing Solution (SSPS)
  • SSPS contains the following in deionized H2O:
  • 1.40 weight % sodium sulfate
  • 0.185 weight % sodium borate [1330-43-4], Mallinckrodt
  • 0.926 weight % boric acid [10043-35-3], Mallinckrodt
  • 0.005 weight % methylcellulose
  • Preparation Lens Type A
  • A hydrogel blend was made from the following monomer mix (all amounts were calculated as weight percent: 30.00% SIMM 2, 28.0% mPDMS, 5.0% acPDMS, 19.0% DMA, 7.15% HEMA, 1.60% MM, 7.00% PVP 360,000, 2.0% Norbloc, 1.0% CGI 819 and 0.02% Blue HEMA, 60 weight percent of the preceding component mixture was further diluted with diluent, 40 weight percent of 72.5:27.5 TAA: PVP 2,500, to form the final monomer mix. The blend placed in a two part contact lens mold and was cured using the following sequential conditions a) room temperature for 30 seconds using a visible light that emits 1 mW/sq cm, b)75° C. 120 seconds, c) 75° C. 120 seconds 1.8 mW/sq/cm, and d) 75° C. 240 seconds 6.0 mW/sq cm. The cured lenses are removed from the molds and hydrated with Di.
  • Example 1 Preparation of Antimicrobial Lenses from Cured Lenses without an Acidic Substance
  • Cured and hydrated lenses of Type A are placed in a jar with sodium iodide solution in deionized water (500-700 ppm), containing 50 ppm of methylcellulose (˜3 mL solution per lens,) and rolled on a jar roller overnight. The lenses were transferred from the jar to a blister pack where the excess sodium iodide solution was removed. A solution (800 μL, 150 ppm) of silver nitrate in deionized water, containing the appropriate dispersion agent, was added to the blister for two to five minutes. The silver nitrate solution was removed, and the lenses were placed in a jar containing deionized water and rolled on a jar roller for approximately thirty minutes. The deionized water was replaced with borate buffered sodium sulfate solution containing 50 ppm methylcellulose water (SSPS), and allowed to roll on the jar roller for an additional 30 minutes. The solution was then replaced with fresh SSPS.
  • The lenses were then transferred to new blisters and dosed with 950 μL of SSPS. The blisters were sealed and autoclaved at 125° C. for 18 minutes and analyzed for silver content using the method described below. The results are presented in FIG. 1. This data shows that increasing the concentration of sodium iodide, unexpectedly reduces the amount of silver iodide deposited into the lens.
  • Silver content of the lenses after lens autoclaving was determined by Instrumental Neutron Activation Analysis “INAA”. INAA is a qualitative and quantitative elemental analysis method based on the artificial induction of specific radionuclides by irradiation with neutrons in a nuclear reactor. Irradiation of the sample is followed by the quantitative measurement of the characteristic gamma rays emitted by the decaying radionuclides. The gamma rays detected at a particular energy are indicative of a particular radionuclide's presence, allowing for a high degree of specificity. Becker, D. A.; Greenberg, R. R.; Stone, S. F. J. Radioanal. Nucl. Chem. 1992, 160(1), 41-53; Becker, D. A.; Anderson, D. L.; Lindstrom, R. M.; Greenberg, R. R.; Garrity, K. M.; Mackey, E. A. J. Radioanal. Nucl. Chem. 1994, 179(1), 149-54. The INAA procedure used to quantify silver content in contact lens material uses the following two nuclear reactions:
      • 1. In the activation reaction, 110Ag is produced from stable 109Ag (isotopic abundance=48.16%) after capture of a radioactive neutron produced in a nuclear reactor.
      • 2. In the decay reaction, 110Ag (τ1/2=24.6 seconds) decays primarily by negatron emission proportional to initial concentration with an energy characteristic to this radio-nuclide (657.8 keV).
        The gamma-ray emission specific to the decay of 110Ag from irradiated. standards and samples are measured by gamma-ray spectroscopy, a well-established pulse-height analysis technique, yielding a measure of the concentration of the analyte.
    Example 2 Preparation of Antimicrobial Lenses from Cured Lenses with an Acidic Substance
  • The procedure of Example 1 was repeated with one exception, 0.05% weight percent of Acetic Acid in deionized water was added to the sodium iodide solution and the silver nitrate solution. The lenses were analyzed for silver content and the data is presented in FIG. 2. This data shows that the acidified process gives the expected increase in the amount of silver iodide deposited in the lens as the amount of sodium nitrate is increased.

Claims (20)

1. A method of preparing an antimicrobial lens comprising a metal salt, wherein said method comprising the steps of
(a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
(b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
2. The method of claim 1 wherein the acidic substance is selected from the group consisting of acetic acid, hydrochloric acid, and sulfuric acid.
3. The method of claim 1 wherein the acidic substance is acetic acid.
4. The method of claim 1 wherein the effective amount of the acidic substance is about 0.01% to about 10%.
5. The method of claim 1 wherein the effective amount of the acidic substance is about 0.5%.
6. The method of claim 1 wherein the effective amount of the acidic substance is about 0.05%.
7. The method of claim 1 wherein the ph of the solution of steps (a) and (b) is about 2 to about 5.
8. The method of claim 1 wherein the ph of the solution of steps (a) and (b) is about 2 to about 4.
9. The method of claim 1 wherein the pH of the solution of steps (a) and (b) is about 3 to about 4.
10. The method of claim 1 wherein the salt precursor is selected from the group consisting of tetra-alkyl ammonium lactate, tetra-alkyl ammonium sulfate, tetra-alkyl ammonium chloride, tetra-alkyl ammonium, bromide, tetra-alkyl ammonium iodide, sodium chloride, sodium iodide, sodium bromide, lithium chloride, lithium sulfide, sodium sulfide, potassium sulfide, and sodium tetrachloro argentate.
11. The method of claim 1 wherein the salt precursor is selected from the group consisting of sodium chloride, sodium iodide, sodium bromide, lithium chloride, lithium sulfide, sodium sulfide, potassium sulfide, and sodium tetrachloro argentite.
12. The method of claim 1 wherein the salt precursor is sodium iodide.
13. The method of claim 1 wherein the metal agent is selected from the group consisting of silver iodide, silver chloride, and silver bromide.
14. The method of claim 1 wherein the salt precursor is selected from the group consisting of silver nitrate, silver triflate, and silver acetate.
15. The method of claim 1 wherein the salt precursor is silver acetate.
16. A method of preparing an antimicrobial lens comprising a metal salt, wherein said method comprising the steps of
(a) treating a cured lens, a solution comprising, consisting essentially of, or consisting of a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
(b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
17. An antimicrobial lens comprising a metal salt, prepared by a method comprising the steps of
(a) treating a cured lens, a solution comprising a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
(b) treating the lens of step (a) with a solution comprising a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
18. The antimicrobial lens of claim 17 wherein the metal salt is silver iodide, the salt precursor is sodium nitrate, the metal agent is silver nitrate and the pH of the solutions of steps (a) and (b) is about 3-4.
19. An antimicrobial lens comprising a metal salt, prepared by a method comprising the steps of
(a) treating a cured lens, a solution comprising a metal agent and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0; and
(b) treating the lens of step (a) with a solution comprising, consisting essentially of, or consisting of a salt precursor and an effective amount of an acidic substance, wherein the pH of said solution is less than about 7.0.
20. The antimicrobial lens of claim 19 wherein the metal salt is silver iodide, the salt precursor is sodium nitrate, the metal agent is silver nitrate and the pH of the solutions of steps (a) and (b) is about 3-4.
US11/923,685 2006-10-31 2007-10-25 Acidic processes to prepare antimicrobial contact lenses Abandoned US20080102095A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/923,685 US20080102095A1 (en) 2006-10-31 2007-10-25 Acidic processes to prepare antimicrobial contact lenses
US13/007,776 US9358317B2 (en) 2006-10-31 2011-01-17 Acidic processes to prepare antimicrobial contact lenses
US15/146,426 US20160242421A1 (en) 2006-10-31 2016-05-04 Acidic processes to prepare antimicrobial contact lenses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86358306P 2006-10-31 2006-10-31
US11/923,685 US20080102095A1 (en) 2006-10-31 2007-10-25 Acidic processes to prepare antimicrobial contact lenses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/007,776 Continuation US9358317B2 (en) 2006-10-31 2011-01-17 Acidic processes to prepare antimicrobial contact lenses

Publications (1)

Publication Number Publication Date
US20080102095A1 true US20080102095A1 (en) 2008-05-01

Family

ID=39345003

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/923,685 Abandoned US20080102095A1 (en) 2006-10-31 2007-10-25 Acidic processes to prepare antimicrobial contact lenses
US13/007,776 Active 2030-11-16 US9358317B2 (en) 2006-10-31 2011-01-17 Acidic processes to prepare antimicrobial contact lenses
US15/146,426 Abandoned US20160242421A1 (en) 2006-10-31 2016-05-04 Acidic processes to prepare antimicrobial contact lenses

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/007,776 Active 2030-11-16 US9358317B2 (en) 2006-10-31 2011-01-17 Acidic processes to prepare antimicrobial contact lenses
US15/146,426 Abandoned US20160242421A1 (en) 2006-10-31 2016-05-04 Acidic processes to prepare antimicrobial contact lenses

Country Status (12)

Country Link
US (3) US20080102095A1 (en)
EP (1) EP2091577A2 (en)
JP (1) JP2010508421A (en)
KR (1) KR20090085092A (en)
CN (1) CN101573146A (en)
AR (1) AR063755A1 (en)
AU (1) AU2007313798A1 (en)
BR (1) BRPI0718290A2 (en)
CA (1) CA2667990A1 (en)
RU (1) RU2465920C2 (en)
TW (1) TW200831143A (en)
WO (1) WO2008055048A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249356A1 (en) * 2008-09-30 2010-09-30 Osman Rathore Ionic silicone hydrogels having improved hydrolytic stability
WO2012064894A1 (en) * 2010-11-09 2012-05-18 Filligent (Hk) Limited Antimicrobial compositions for incorporation into polymers
US9101667B2 (en) 2008-09-30 2015-08-11 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels comprising pharmaceutical and/or neuticeutical components and having improved hydrolytic stability

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524689A (en) * 2018-06-22 2018-09-14 陕西杨凌陕特农业发展有限公司 A kind of Medical invisible eye care liquid and preparation method thereof

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408429A (en) * 1963-09-11 1968-10-29 Ceskoslovenska Akademie Ved Method for centrifugal casting a contact lens
US3660545A (en) * 1961-12-27 1972-05-02 Ceskoslovenska Akademie Ved Method of centrifugally casting thin edged corneal contact lenses
US3808178A (en) * 1972-06-16 1974-04-30 Polycon Laboratories Oxygen-permeable contact lens composition,methods and article of manufacture
US4113224A (en) * 1975-04-08 1978-09-12 Bausch & Lomb Incorporated Apparatus for forming optical lenses
US4120570A (en) * 1976-06-22 1978-10-17 Syntex (U.S.A.) Inc. Method for correcting visual defects, compositions and articles of manufacture useful therein
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4139513A (en) * 1977-11-08 1979-02-13 Toyo Contact Lens Co., Ltd. Copolymer for soft contact lens, its preparation and soft contact lens made thereof
US4139692A (en) * 1977-10-12 1979-02-13 Toyo Contact Lens Co., Ltd. Copolymer for contact lens, its preparation and contact lens made thereof
US4153641A (en) * 1977-07-25 1979-05-08 Bausch & Lomb Incorporated Polysiloxane composition and contact lens
US4182822A (en) * 1976-11-08 1980-01-08 Chang Sing Hsiung Hydrophilic, soft and oxygen permeable copolymer composition
US4189546A (en) * 1977-07-25 1980-02-19 Bausch & Lomb Incorporated Polysiloxane shaped article for use in biomedical applications
US4197266A (en) * 1974-05-06 1980-04-08 Bausch & Lomb Incorporated Method for forming optical lenses
US4254248A (en) * 1979-09-13 1981-03-03 Bausch & Lomb Incorporated Contact lens made from polymers of polysiloxane and polycyclic esters of acrylic acid or methacrylic acid
US4259467A (en) * 1979-12-10 1981-03-31 Bausch & Lomb Incorporated Hydrophilic contact lens made from polysiloxanes containing hydrophilic sidechains
US4260725A (en) * 1979-12-10 1981-04-07 Bausch & Lomb Incorporated Hydrophilic contact lens made from polysiloxanes which are thermally bonded to polymerizable groups and which contain hydrophilic sidechains
US4261875A (en) * 1979-01-31 1981-04-14 American Optical Corporation Contact lenses containing hydrophilic silicone polymers
US4276402A (en) * 1979-09-13 1981-06-30 Bausch & Lomb Incorporated Polysiloxane/acrylic acid/polcyclic esters of methacrylic acid polymer contact lens
US4301012A (en) * 1979-04-25 1981-11-17 Purolator Technologies, Inc. Welded stainless steel mesh cleanable filter
US4327203A (en) * 1981-02-26 1982-04-27 Bausch & Lomb Incorporated Polysiloxane with cycloalkyl modifier composition and biomedical devices
US4330383A (en) * 1978-07-18 1982-05-18 Polymer Technology Corporation Dimensionally stable oxygen permeable hard contact lens material and method of manufacture
US4341889A (en) * 1981-02-26 1982-07-27 Bausch & Lomb Incorporated Polysiloxane composition and biomedical devices
US4343927A (en) * 1976-11-08 1982-08-10 Chang Sing Hsiung Hydrophilic, soft and oxygen permeable copolymer compositions
US4355147A (en) * 1981-02-26 1982-10-19 Bausch & Lomb Incorporated Polysiloxane with polycyclic modifier composition and biomedical devices
US4450264A (en) * 1982-08-09 1984-05-22 Polymatic Investment Corp., N.V. Siloxane-containing polymers and contact lenses therefrom
US4463149A (en) * 1982-03-29 1984-07-31 Polymer Technology Corporation Silicone-containing contact lens material and contact lenses made thereof
US4486577A (en) * 1982-10-12 1984-12-04 Ciba-Geigy Corporation Strong, silicone containing polymers with high oxygen permeability
US4495313A (en) * 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
US4525563A (en) * 1983-04-06 1985-06-25 Toyo Contact Lens Co. Oxygen permeable soft contact lens composition
US4543398A (en) * 1983-04-28 1985-09-24 Minnesota Mining And Manufacturing Company Ophthalmic devices fabricated from urethane acrylates of polysiloxane alcohols
US4605712A (en) * 1984-09-24 1986-08-12 Ciba-Geigy Corporation Unsaturated polysiloxanes and polymers thereof
US4661575A (en) * 1982-01-25 1987-04-28 Hercules Incorporated Dicyclopentadiene polymer product
US4680336A (en) * 1984-11-21 1987-07-14 Vistakon, Inc. Method of forming shaped hydrogel articles
US4703097A (en) * 1986-04-10 1987-10-27 Bayer Aktiengesellschaft Optical contact objects
US4711943A (en) * 1985-04-26 1987-12-08 Sola U.S.A. Inc. Hydrophilic siloxane monomers and dimers for contact lens materials, and contact lenses fabricated therefrom
US4725277A (en) * 1986-05-14 1988-02-16 Precision-Cosmet Co., Inc. Intraocular lens with tapered haptics
US4731079A (en) * 1986-11-26 1988-03-15 Kingston Technologies, Inc. Intraocular lenses
US4743447A (en) * 1985-01-30 1988-05-10 L'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Composition for disinfecting contact lenses
US4837289A (en) * 1987-04-30 1989-06-06 Ciba-Geigy Corporation UV- and heat curable terminal polyvinyl functional macromers and polymers thereof
US4863464A (en) * 1988-01-26 1989-09-05 The Cooper Companies, Inc. Intraocular lens
US4871785A (en) * 1986-08-13 1989-10-03 Michael Froix Clouding-resistant contact lens compositions
US4872876A (en) * 1988-05-11 1989-10-10 Nestle S.A. Universal fit intraocular lens
US4889664A (en) * 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
US4954586A (en) * 1989-01-17 1990-09-04 Menicon Co., Ltd Soft ocular lens material
US5010141A (en) * 1989-10-25 1991-04-23 Ciba-Geigy Corporation Reactive silicone and/or fluorine containing hydrophilic prepolymers and polymers thereof
US5034461A (en) * 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
US5039459A (en) * 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US5057578A (en) * 1990-04-10 1991-10-15 E. I. Du Pont De Nemours And Company Silicone-containing block copolymers and macromonomers
US5070215A (en) * 1989-05-02 1991-12-03 Bausch & Lomb Incorporated Novel vinyl carbonate and vinyl carbamate contact lens material monomers
US5314960A (en) * 1990-04-10 1994-05-24 Permeable Technologies, Inc. Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment
US5336797A (en) * 1992-12-30 1994-08-09 Bausch & Lomb Incorporated Siloxane macromonomers
US5346946A (en) * 1992-08-26 1994-09-13 Menicon Co., Ltd Ocular lens material
US5358995A (en) * 1992-05-15 1994-10-25 Bausch & Lomb Incorporated Surface wettable silicone hydrogels
US5371147A (en) * 1990-10-11 1994-12-06 Permeable Technologies, Inc. Silicone-containing acrylic star polymers, block copolymers and macromonomers
US5451617A (en) * 1991-09-12 1995-09-19 Bausch & Lomb Incorporated Wettable silicone hydrogel compositions and methods for their manufacture
US5486579A (en) * 1991-11-05 1996-01-23 Bausch & Lomb Incorporated Wettable silicone hydrogel compositions and methods for their manufacture
US5710302A (en) * 1995-12-07 1998-01-20 Bausch & Lomb Incorporated Monomeric units useful for reducing the modules of silicone hydrogels
US5714557A (en) * 1995-12-07 1998-02-03 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of low water polymeric silicone compositions
US5760100A (en) * 1994-09-06 1998-06-02 Ciba Vision Corporation Extended wear ophthalmic lens
US5776999A (en) * 1994-09-06 1998-07-07 Ciba Vision Corporation Methods of using and screening extended wear ophthalmic lenses
US5807944A (en) * 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
US5944853A (en) * 1992-10-26 1999-08-31 Johnson & Johnson Vision Products, Inc. Method for preparing halotriazine dye- and vinyl sulfone dye-monomer compounds
US5958440A (en) * 1992-05-19 1999-09-28 Westaim Technologies, Inc. Anti-microbial materials
US5962548A (en) * 1998-03-02 1999-10-05 Johnson & Johnson Vision Products, Inc. Silicone hydrogel polymers
US5981615A (en) * 1995-06-14 1999-11-09 Ciba Vision Corporation Polymerizable siloxane macromonomers
US5981675A (en) * 1998-12-07 1999-11-09 Bausch & Lomb Incorporated Silicone-containing macromonomers and low water materials
US5998498A (en) * 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US6020445A (en) * 1997-10-09 2000-02-01 Johnson & Johnson Vision Products, Inc. Silicone hydrogel polymers
US6039913A (en) * 1998-08-27 2000-03-21 Novartis Ag Process for the manufacture of an ophthalmic molding
US6087415A (en) * 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US20030095230A1 (en) * 2001-08-02 2003-05-22 Neely Frank L. Antimicrobial lenses and methods of their use related patent applications
US6585768B2 (en) * 1997-12-02 2003-07-01 Hoya Healthcare Corporation Intraocular lenses and process for the producing molded-in type intraocular lenses
US20040150788A1 (en) * 2002-11-22 2004-08-05 Ann-Margret Andersson Antimicrobial lenses, processes to prepare them and methods of their use
US20050008676A1 (en) * 2002-12-19 2005-01-13 Yongxing Qiu Medical devices having antimicrobial coatings thereon
US7319133B2 (en) * 2005-08-09 2008-01-15 Coopervision, Inc. Contact lens extraction/hydration systems and methods of reprocessing fluids used therein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410442A (en) 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US5115056A (en) 1989-06-20 1992-05-19 Ciba-Geigy Corporation Fluorine and/or silicone containing poly(alkylene-oxide)-block copolymers and contact lenses thereof
JPH06123860A (en) 1992-10-09 1994-05-06 Tokyo Keikaku:Kk Oxygen permeable hard contact lens
US5472703A (en) * 1993-03-02 1995-12-05 Johnson & Johnson Vision Products, Inc. Ophthalmic lens with anti-toxin agent
US5374662A (en) 1993-03-15 1994-12-20 Bausch & Lomb Incorporated Fumarate and fumaramide siloxane hydrogel compositions
FR2772033A1 (en) 1997-12-05 1999-06-04 Essilor Int PROCESS FOR PRODUCING A TRANSPARENT POLYMERIC MATERIAL RESISTANT TO THE DEPOSITION OF PROTEINS, MATERIAL OBTAINED BY THIS PROCESS, CONTACT LENSES AND INTRAOCULAR IMPLANTS MADE OF THIS MATERIAL
US7052131B2 (en) 2001-09-10 2006-05-30 J&J Vision Care, Inc. Biomedical devices containing internal wetting agents
FR2777284B1 (en) * 1998-04-10 2000-05-26 Hamza Mansour PROCESS FOR THE STERILIZATION OF A NATIVE COLLAGEN IN A LIQUID MEDIUM, A STERILE NATIVE COLLAGEN OBTAINED, COMPOSITIONS CONTAINING THE SAME AND APPLICATIONS
JP2000010055A (en) 1998-06-19 2000-01-14 Seed Co Ltd Hydrophilic lens for eye and its production
JP2000016905A (en) 1998-07-01 2000-01-18 Tokuriki Kagaku Kenkyusho:Kk Antibacterial-fungal agent and antibacterial-fungal material
JP3824791B2 (en) 1998-10-01 2006-09-20 株式会社ニデック Manufacturing method of intraocular lens
SE9803481D0 (en) 1998-10-13 1998-10-13 Pharmacia & Upjohn Ab Photocurable siloxane polymers
KR100871500B1 (en) 1998-10-13 2008-12-05 에이엠오 그로닌겐 비.브이. Injectable intraocular lens
WO2000026698A1 (en) 1998-10-29 2000-05-11 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions
DE10024363A1 (en) * 2000-05-17 2001-11-29 Woehlk Contact Linsen Gmbh Silver impregnated contact lens comprises body formed of matrix with silver with sulfide, halogenide and oxide, with silver precipitated and diffused
US20020197299A1 (en) 2000-12-21 2002-12-26 Vanderlaan Douglas G. Antimicrobial contact lenses containing activated silver and methods for their production
US20030044447A1 (en) * 2000-12-21 2003-03-06 Diana Zanini Antimicrobial contact lenses and methods for their production
AU2002246868B2 (en) 2001-08-02 2007-05-31 Johnson & Johnson Vision Care, Inc. Antimicrobial lenses and methods of their use
WO2004047878A1 (en) * 2002-11-22 2004-06-10 Johnson & Johnson Vision Care, Inc. Antimicrobial lenses displaying extended efficacy
US7416737B2 (en) * 2003-11-18 2008-08-26 Johnson & Johnson Vision Care, Inc. Antimicrobial lenses, processes to prepare them and methods of their use
US7960465B2 (en) * 2006-06-30 2011-06-14 Johnson & Johnson Vision Care, Inc. Antimicrobial lenses, processes to prepare them and methods of their use
US20080100797A1 (en) * 2006-10-31 2008-05-01 Nayiby Alvarez-Carrigan Antimicrobial contact lenses with reduced haze and preparation thereof
KR20090101894A (en) * 2006-10-31 2009-09-29 존슨 앤드 존슨 비젼 케어, 인코포레이티드 Processes to prepare antimicrobial contact lenses

Patent Citations (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660545A (en) * 1961-12-27 1972-05-02 Ceskoslovenska Akademie Ved Method of centrifugally casting thin edged corneal contact lenses
US3408429A (en) * 1963-09-11 1968-10-29 Ceskoslovenska Akademie Ved Method for centrifugal casting a contact lens
US3808178A (en) * 1972-06-16 1974-04-30 Polycon Laboratories Oxygen-permeable contact lens composition,methods and article of manufacture
US4197266A (en) * 1974-05-06 1980-04-08 Bausch & Lomb Incorporated Method for forming optical lenses
US4113224A (en) * 1975-04-08 1978-09-12 Bausch & Lomb Incorporated Apparatus for forming optical lenses
US4120570A (en) * 1976-06-22 1978-10-17 Syntex (U.S.A.) Inc. Method for correcting visual defects, compositions and articles of manufacture useful therein
US4182822A (en) * 1976-11-08 1980-01-08 Chang Sing Hsiung Hydrophilic, soft and oxygen permeable copolymer composition
US4343927A (en) * 1976-11-08 1982-08-10 Chang Sing Hsiung Hydrophilic, soft and oxygen permeable copolymer compositions
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4189546A (en) * 1977-07-25 1980-02-19 Bausch & Lomb Incorporated Polysiloxane shaped article for use in biomedical applications
US4153641A (en) * 1977-07-25 1979-05-08 Bausch & Lomb Incorporated Polysiloxane composition and contact lens
US4139692A (en) * 1977-10-12 1979-02-13 Toyo Contact Lens Co., Ltd. Copolymer for contact lens, its preparation and contact lens made thereof
US4139513A (en) * 1977-11-08 1979-02-13 Toyo Contact Lens Co., Ltd. Copolymer for soft contact lens, its preparation and soft contact lens made thereof
US4330383A (en) * 1978-07-18 1982-05-18 Polymer Technology Corporation Dimensionally stable oxygen permeable hard contact lens material and method of manufacture
US4261875A (en) * 1979-01-31 1981-04-14 American Optical Corporation Contact lenses containing hydrophilic silicone polymers
US4301012A (en) * 1979-04-25 1981-11-17 Purolator Technologies, Inc. Welded stainless steel mesh cleanable filter
US4254248A (en) * 1979-09-13 1981-03-03 Bausch & Lomb Incorporated Contact lens made from polymers of polysiloxane and polycyclic esters of acrylic acid or methacrylic acid
US4276402A (en) * 1979-09-13 1981-06-30 Bausch & Lomb Incorporated Polysiloxane/acrylic acid/polcyclic esters of methacrylic acid polymer contact lens
US4259467A (en) * 1979-12-10 1981-03-31 Bausch & Lomb Incorporated Hydrophilic contact lens made from polysiloxanes containing hydrophilic sidechains
US4260725A (en) * 1979-12-10 1981-04-07 Bausch & Lomb Incorporated Hydrophilic contact lens made from polysiloxanes which are thermally bonded to polymerizable groups and which contain hydrophilic sidechains
US4341889A (en) * 1981-02-26 1982-07-27 Bausch & Lomb Incorporated Polysiloxane composition and biomedical devices
US4327203A (en) * 1981-02-26 1982-04-27 Bausch & Lomb Incorporated Polysiloxane with cycloalkyl modifier composition and biomedical devices
US4355147A (en) * 1981-02-26 1982-10-19 Bausch & Lomb Incorporated Polysiloxane with polycyclic modifier composition and biomedical devices
US4495313A (en) * 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
US4661575A (en) * 1982-01-25 1987-04-28 Hercules Incorporated Dicyclopentadiene polymer product
US4463149A (en) * 1982-03-29 1984-07-31 Polymer Technology Corporation Silicone-containing contact lens material and contact lenses made thereof
US4450264A (en) * 1982-08-09 1984-05-22 Polymatic Investment Corp., N.V. Siloxane-containing polymers and contact lenses therefrom
US4486577A (en) * 1982-10-12 1984-12-04 Ciba-Geigy Corporation Strong, silicone containing polymers with high oxygen permeability
US4525563A (en) * 1983-04-06 1985-06-25 Toyo Contact Lens Co. Oxygen permeable soft contact lens composition
US4543398A (en) * 1983-04-28 1985-09-24 Minnesota Mining And Manufacturing Company Ophthalmic devices fabricated from urethane acrylates of polysiloxane alcohols
US4605712A (en) * 1984-09-24 1986-08-12 Ciba-Geigy Corporation Unsaturated polysiloxanes and polymers thereof
US4680336A (en) * 1984-11-21 1987-07-14 Vistakon, Inc. Method of forming shaped hydrogel articles
US4743447A (en) * 1985-01-30 1988-05-10 L'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Composition for disinfecting contact lenses
US4711943A (en) * 1985-04-26 1987-12-08 Sola U.S.A. Inc. Hydrophilic siloxane monomers and dimers for contact lens materials, and contact lenses fabricated therefrom
US4703097A (en) * 1986-04-10 1987-10-27 Bayer Aktiengesellschaft Optical contact objects
US4725277A (en) * 1986-05-14 1988-02-16 Precision-Cosmet Co., Inc. Intraocular lens with tapered haptics
US4871785A (en) * 1986-08-13 1989-10-03 Michael Froix Clouding-resistant contact lens compositions
US4731079A (en) * 1986-11-26 1988-03-15 Kingston Technologies, Inc. Intraocular lenses
US4837289A (en) * 1987-04-30 1989-06-06 Ciba-Geigy Corporation UV- and heat curable terminal polyvinyl functional macromers and polymers thereof
US4863464A (en) * 1988-01-26 1989-09-05 The Cooper Companies, Inc. Intraocular lens
US4872876A (en) * 1988-05-11 1989-10-10 Nestle S.A. Universal fit intraocular lens
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
US4889664A (en) * 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US5039459A (en) * 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US4954586A (en) * 1989-01-17 1990-09-04 Menicon Co., Ltd Soft ocular lens material
US5070215A (en) * 1989-05-02 1991-12-03 Bausch & Lomb Incorporated Novel vinyl carbonate and vinyl carbamate contact lens material monomers
US5034461A (en) * 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
US5010141A (en) * 1989-10-25 1991-04-23 Ciba-Geigy Corporation Reactive silicone and/or fluorine containing hydrophilic prepolymers and polymers thereof
US5057578A (en) * 1990-04-10 1991-10-15 E. I. Du Pont De Nemours And Company Silicone-containing block copolymers and macromonomers
US5314960A (en) * 1990-04-10 1994-05-24 Permeable Technologies, Inc. Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment
US5371147A (en) * 1990-10-11 1994-12-06 Permeable Technologies, Inc. Silicone-containing acrylic star polymers, block copolymers and macromonomers
US5451617A (en) * 1991-09-12 1995-09-19 Bausch & Lomb Incorporated Wettable silicone hydrogel compositions and methods for their manufacture
US5486579A (en) * 1991-11-05 1996-01-23 Bausch & Lomb Incorporated Wettable silicone hydrogel compositions and methods for their manufacture
US5358995A (en) * 1992-05-15 1994-10-25 Bausch & Lomb Incorporated Surface wettable silicone hydrogels
US5387632A (en) * 1992-05-15 1995-02-07 Bausch & Lomb Incorporated Surface wettable silicone hydrogels
US5958440A (en) * 1992-05-19 1999-09-28 Westaim Technologies, Inc. Anti-microbial materials
US5346946A (en) * 1992-08-26 1994-09-13 Menicon Co., Ltd Ocular lens material
US5944853A (en) * 1992-10-26 1999-08-31 Johnson & Johnson Vision Products, Inc. Method for preparing halotriazine dye- and vinyl sulfone dye-monomer compounds
US5336797A (en) * 1992-12-30 1994-08-09 Bausch & Lomb Incorporated Siloxane macromonomers
US5849811A (en) * 1994-09-06 1998-12-15 Ciba Vision Corporation Extended wear ophthalmic lens
US5789461A (en) * 1994-09-06 1998-08-04 Ciba Vision Corporation Methods of forming an extended wear ophthalmic lens having a hydrophilic surface
US5789461B1 (en) * 1994-09-06 2000-11-21 Ciba Vision Corp Methods of forming an extended wear ophthalmic lens having a hydrophilic surface
US5760100A (en) * 1994-09-06 1998-06-02 Ciba Vision Corporation Extended wear ophthalmic lens
US5776999B1 (en) * 1994-09-06 2000-11-21 Ciba Vision Corp Methods of using and screening extended wear opthalmic lenses
US5760100B1 (en) * 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
US5776999A (en) * 1994-09-06 1998-07-07 Ciba Vision Corporation Methods of using and screening extended wear ophthalmic lenses
US5849811B1 (en) * 1994-09-06 2000-11-14 Ciba Vision Corporatin Extended wear ophthalmic lens
US5965631A (en) * 1994-09-06 1999-10-12 Ciba Vision Corporation Extended wear ophthalmic lens
US5981615A (en) * 1995-06-14 1999-11-09 Ciba Vision Corporation Polymerizable siloxane macromonomers
US5710302A (en) * 1995-12-07 1998-01-20 Bausch & Lomb Incorporated Monomeric units useful for reducing the modules of silicone hydrogels
US5714557A (en) * 1995-12-07 1998-02-03 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of low water polymeric silicone compositions
US5908906A (en) * 1995-12-07 1999-06-01 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of silicone hydrogels
US5807944A (en) * 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
US6020445A (en) * 1997-10-09 2000-02-01 Johnson & Johnson Vision Products, Inc. Silicone hydrogel polymers
US6585768B2 (en) * 1997-12-02 2003-07-01 Hoya Healthcare Corporation Intraocular lenses and process for the producing molded-in type intraocular lenses
US5998498A (en) * 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US5962548A (en) * 1998-03-02 1999-10-05 Johnson & Johnson Vision Products, Inc. Silicone hydrogel polymers
US6087415A (en) * 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6039913A (en) * 1998-08-27 2000-03-21 Novartis Ag Process for the manufacture of an ophthalmic molding
US5981675A (en) * 1998-12-07 1999-11-09 Bausch & Lomb Incorporated Silicone-containing macromonomers and low water materials
US20030095230A1 (en) * 2001-08-02 2003-05-22 Neely Frank L. Antimicrobial lenses and methods of their use related patent applications
US20040150788A1 (en) * 2002-11-22 2004-08-05 Ann-Margret Andersson Antimicrobial lenses, processes to prepare them and methods of their use
US20050008676A1 (en) * 2002-12-19 2005-01-13 Yongxing Qiu Medical devices having antimicrobial coatings thereon
US7319133B2 (en) * 2005-08-09 2008-01-15 Coopervision, Inc. Contact lens extraction/hydration systems and methods of reprocessing fluids used therein

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249356A1 (en) * 2008-09-30 2010-09-30 Osman Rathore Ionic silicone hydrogels having improved hydrolytic stability
US8470906B2 (en) * 2008-09-30 2013-06-25 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
US8815972B2 (en) 2008-09-30 2014-08-26 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
US9101667B2 (en) 2008-09-30 2015-08-11 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels comprising pharmaceutical and/or neuticeutical components and having improved hydrolytic stability
US9260544B2 (en) 2008-09-30 2016-02-16 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels having improved hydrolytic stability
WO2012064894A1 (en) * 2010-11-09 2012-05-18 Filligent (Hk) Limited Antimicrobial compositions for incorporation into polymers

Also Published As

Publication number Publication date
RU2465920C2 (en) 2012-11-10
US9358317B2 (en) 2016-06-07
EP2091577A2 (en) 2009-08-26
AR063755A1 (en) 2009-02-18
RU2009120572A (en) 2010-12-10
WO2008055048A2 (en) 2008-05-08
AU2007313798A1 (en) 2008-05-08
KR20090085092A (en) 2009-08-06
WO2008055048A3 (en) 2008-09-12
BRPI0718290A2 (en) 2013-11-19
CN101573146A (en) 2009-11-04
US20160242421A1 (en) 2016-08-25
TW200831143A (en) 2008-08-01
CA2667990A1 (en) 2008-05-08
US20110111001A1 (en) 2011-05-12
JP2010508421A (en) 2010-03-18

Similar Documents

Publication Publication Date Title
US7416737B2 (en) Antimicrobial lenses, processes to prepare them and methods of their use
EP1599236A1 (en) Antimicrobial lenses displaying extended efficacy
US20160242421A1 (en) Acidic processes to prepare antimicrobial contact lenses
WO2004047878A1 (en) Antimicrobial lenses displaying extended efficacy
US20080241225A1 (en) Basic processes to prepare antimicrobial contact lenses
EP2091578B1 (en) Antimicrobial contact lens and processes to prepare antimicrobial contact lenses
US8361355B2 (en) Preparation of antimicrobial contact lenses with reduced haze using swelling agents
AU2007313837B2 (en) Antimicrobial contact lenses with reduced haze and preparation thereof
EP1769809A2 (en) Antimicrobial lenses displaying extended efficacy, processes to prepare them and methods of their use

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON & JOHNSON VISION CARE, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOUNG, KENT;RATHORE, OSMAN;ALVAREZ-CARRIGAN, NAYIBY;AND OTHERS;REEL/FRAME:020368/0873;SIGNING DATES FROM 20071129 TO 20071218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION